| URL | https://www.biospace.com/article/allogene-opens-ne |
| Source | https://www.biospace.com |
| Date Published | 04/15/2022 |
| Author Name | Alex Keown |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Allogene Therapeutics |
| Parent company | Allogene Therapeutics |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Newark |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | CAR-T therapies, anti-CD19 AlloCAR T |